Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

by O’Shaughnessy, Joyce A. , Lévy, Christelle , Jacot, William , Saura, Cristina , Patel, Gargi , Curigliano, Giuseppe , Wildiers, Hans , Begbie, Natasha , Pierga, Jean-Yves , Dent, Rebecca , Zhang, Qingyuan , Biganzoli, Laura , Bardia, Aditya , Yonemori, Kan , Hu, Xichun , Barrios, Carlos H. , Sohn, Joohyuk , Im, Seock-Ah , Ke, Jun

in Adult / Aged / Aged, 80 and over / Antineoplastic Agents, Hormonal - administration & dosage / Antineoplastic Agents, Hormonal - adverse effects / Antineoplastic Agents, Immunological - administration & dosage / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Breast Cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - mortality / Breast Neoplasms - pathology / Camptothecin - administration & dosage / Camptothecin - adverse effects / Camptothecin - analogs & derivatives / Cancer therapies / Chemotherapy / Collaboration / Cyclin-dependent kinases / Endocrine therapy / ErbB-2 protein / Female / Hematology / Humans / Hybridization / Immunoconjugates - administration & dosage / Immunoconjugates - adverse effects / Kaplan-Meier Estimate / Kinases / Lung diseases / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Oncology / Patient safety / Pneumonitis / Progression-Free Survival / Receptor, ErbB-2 - analysis / Receptor, ErbB-2 - metabolism / Receptors, Estrogen - analysis / Receptors, Estrogen - metabolism / Survival / Targeted cancer therapy / Trastuzumab / Trastuzumab - administration & dosage / Trastuzumab - adverse effects / Treatment Outcome / Treatments in Oncology / Tumors

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

2024

Confirm

Do you wish to request the book?

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

O’Shaughnessy, Joyce A.,

Lévy, Christelle,

Jacot, William,

Saura, Cristina,

Patel, Gargi,

Curigliano, Giuseppe,

Wildiers, Hans,

Begbie, Natasha,

Pierga, Jean-Yves,

Dent, Rebecca,

Zhang, Qingyuan,

Biganzoli, Laura,

Bardia, Aditya,

Yonemori, Kan,

Hu, Xichun,

Barrios, Carlos H.,

Sohn, Joohyuk,

Im, Seock-Ah,

Ke, Jun

2024

Overview

Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Agents, Hormonal - administration & dosage

/ Antineoplastic Agents, Hormonal - adverse effects

/ Antineoplastic Agents, Immunological - administration & dosage

/ Antineoplastic Agents, Immunological - adverse effects